Clinical Trials

Papers
(The TQCC of Clinical Trials is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Impact of correlation structure on sample size requirements of statistical methods for multiple binary outcomes: A simulation study40
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy31
A randomized comparison of two-stage versus traditional one-stage consent for a low-stakes randomized trial29
Abstracts from the Society for Clinical Trials 45th Annual Meeting (2024)23
Ethics challenges in sharing data from pragmatic clinical trials22
Clinical trials in Russia21
Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges21
Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom20
Inferences for the distribution of the duration of response in a comparative clinical study20
Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study20
Research encouraging off-label use of quetiapine: A systematic meta-epidemiological analysis19
Industry payments and brand-name tyrosine kinase inhibitor use amid generic entry18
On the proposed use of a finite-population correction factor in clinical trials18
Statistical approaches for component-wise censored composite endpoints17
What do we do with our under-enrolled single-center COVID-19 clinical trials?16
Poor effort on cognitive testing in voluntary research predicts failure in US Army Ranger School: Implications for clinical trial design15
Testing Meldonium: Assessing Soviet pragmatic alternatives to the randomized controlled trial15
Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials15
Bringing data monitoring committee charters into the sunlight14
A critique on “A randomized evaluation of on-site monitoring nested in a multinational randomized trial”14
Analysis of adaptive platform trials using a network approach14
Effects of patient-reported outcome assessment order14
Thirteenth annual UPenn conference on statistical issues in clinical trials: Cluster randomized clinical trials—opportunities and challenges (morning panel session)13
Contributed Presentations12
Successful completion of large, low-cost randomized cancer trials at an academic cancer center12
Dynamic use of historical controls in clinical trials for rare disease research: A re-evaluation of the MILES trial12
Use of comprehensive recruitment strategies in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE) multi-center clinical trial11
Commentary on Price and Scott: Complex innovative trial design10
A review of current practice in the design and analysis of extremely small stepped-wedge cluster randomized trials10
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials10
Session Proposals10
UK paediatric clinical trial protocols: A review of guidance for participant management and care in the event of premature termination9
Book Review – For the common good9
Are self-reported and self-monitored adherence good proxies for reaching relevant plasma concentrations?: Experiences from a study of anti-depressants in healthy volunteers9
Dose optimization for cancer treatments with considerations for late-onset toxicities9
Abstracts from the society for clinical trials 44th annual meeting (2023)9
Using multistate models with clinical trial data for a deeper understanding of complex disease processes9
The influence of political ideology on clinical trial knowledge, invitation, and participation among adults in the United States9
Adherence to key recommendations for design and analysis of stepped-wedge cluster randomized trials: A review of trials published 2016–20229
A model for conducting clinical trials via telemedicine8
Risk-proportionate approach to paediatric clinical trials: The legal requirements, challenges, and the way forward under the European Union Clinical Trials Regulation8
Causal interpretation of the hazard ratio in randomized clinical trials8
Rethinking intercurrent events in defining estimands for tuberculosis trials8
Aspirin in primary prevention: Undue reliance on an uninformative trial led to misinformed clinical guidelines7
Using modified intention-to-treat as a principal stratum estimator for failure to initiate treatment7
Intra-cluster correlations from the CLustered OUtcome Dataset bank to inform the design of longitudinal cluster trials7
Commentary on Wittes et al: Aspirin for primary prevention of CV events – Rationally robust? Statistically significant? Clinically convincing?7
Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial7
Random effect misspecification in stepped wedge designs7
Assessing the impact of risk-based data monitoring on outcomes for a paediatric multicentre randomised controlled trial7
Now is the time to fix the clinical research workforce crisis7
Optimal one-stage design and analysis for efficacy expansion in Phase I oncology trials6
Society for Clinical Trials Data Monitoring Committee initiative website: Closing the gap6
Improving data monitoring in Australian clinical trials and research: Free resources and templates6
Design and implementation of community consultation for research conducted under exception from informed consent regulations for the PreVent and the PreVent 2 trials: Changes over time and during the 6
The improving Medication Adherence in Adolescents and young adults following Liver Transplantation (iMALT) multisite trial: Design and trial implementation considerations6
Modeling impact of inflation reduction act price negotiations on new drug pipeline considering differential contributions of large and small biopharmaceutical companies6
Importance of patient engagement in the conduct of pragmatic multicenter randomized controlled trials: The ADAPTABLE experience6
Improving clinical trial transparency at UK universities: Evaluating 3 years of policies and reporting performance on the European Clinical Trial Register6
Constructing and evaluating a validity argument for a performance outcome measure for clinical trials: An example using the Multi-luminance Mobility Test6
Considerations for open-label randomized clinical trials: Design, conduct, and analysis6
Time trends with response-adaptive randomization: The inevitability of inefficiency6
Cost-effective clinical trial design: Application of a Bayesian sequential model to the ProFHER pragmatic trial6
Taking clinical decisions seriously in standard-of-care pragmatic clinical trials5
Partner engagement for planning and development of non-pharmacological care pathways in the AIM-Back trial5
Concordance between clinical trial data use request proposals and corresponding publications: A cross-sectional study5
2023 Peer Reviewers5
Success of blinding a procedural intervention in a randomised controlled trial in preterm infants receiving respiratory support5
Large-scale prevention trials could provide stronger evidence for decision-makers: Opportunities to design and report with a focus on the benefit–harm balance5
The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial5
Commentary on Aschmann et al: How do we incorporate harms in analyses of randomized trials?5
Randomization: Beyond the closurization principle5
An example of implementing a safety protocol in remote intervention and survey research with college students5
Practical issues in pragmatic trials: the implementation of the Diuretic Comparison Project5
Choosing and changing the analysis scale in non-inferiority trials with a binary outcome5
BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials4
Clinical trial site identification practices and the use of electronic health records in feasibility evaluations: An interview study in the Nordic countries4
2024 Peer Reviewers4
Optimizing the doses of cancer drugs after usual dose finding4
Now is the time to fix the evidence generation system4
Can quality management drive evidence generation?4
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses4
Consent to recontact for future research using linked primary healthcare data: Outcomes and general practice perceptions from the ATHENA COVID-19 study4
Designing and implementing methodology for double-blind, placebo-controlled clinical trials using blood products within the Department of Veterans Affairs4
Estimands in clinical trials of complex disease processes4
Influential methods reports for group-randomized trials and related designs4
Commentary on Chirkova et al.: Some comments on “socialist pharmapolitics”4
The net benefit for time-to-event outcome in oncology clinical trials with treatment switching4
Strategies to promote contraception use by female volunteers in Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease (API ADAD) Colombia trial4
Characterization of studies considered and required under Medicare’s coverage with evidence development program4
Design and logistical considerations for the randomized adaptive non-inferiority storage-duration-ranging CHIlled Platelet Study4
Proceedings of the University of Pennsylvania 14th annual conference on statistical issues in clinical trials: Subgroup analysis in randomized clinical trials—Challenges and opportunities4
Navigating COVID-19 and related challenges to completing clinical trials: Lessons from the PATRIOT and STEP-UP randomized prevention trials4
A Bayesian dose-finding design for outcomes evaluated with uncertainty4
Thirteenth annual UPenn conference on statistical issues in clinical trials: Cluster-randomized clinical trials—opportunities and challenges (afternoon panel session)4
0.094408988952637